Freedom Capital Markets maintains Tempus AI at Hold, raises price target to $89 from $73

Freedom Capital Markets kept Tempus AI at Hold, raising its price target to $89 from $73, a 21.9% increase. The new target implies a 13.4% upside from the Nov 2 close of $78.48. Recent analyst notes on Tempus AI have price targets ranging from $70 to $100.

Original reporting
Published Nov 3, 2026, 7:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 7:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Freedom Capital Markets maintains Tempus AI at Hold, raises price target to $89 from $73 — source image
Decision brief

The 30-second read

$TEMBullishLow
01

Why it matters

This is primarily a valuation narrative update. Without new earnings, guidance, trial results, or corporate actions, it is more likely to influence near-term sentiment than fundamentals.

02

Market read

Useful for tracking sentiment and PT dispersion, but it does not introduce a new fundamental catalyst.

03

What to watch

Traders may weigh the PT range ($70 to $100 across recent notes) and the lack of a rating upgrade, treating this as incremental rather than decisive.

Relevance 4/10Novelty 4/10Timing: as of the analyst note publication date, for positioning around ongoing PT revisions

Background

The piece summarizes an analyst action from Freedom Capital Markets on Tempus AI, including a revised price target and the implied upside versus the Nov 2 close.

Company-level read

Ticker impact

$TEMBullishMedium confidence
Context

Freedom Capital Markets maintained Tempus AI at Hold and raised its price target to $89 from $73, implying a higher valuation outlook.

Expected impact

Likely modest upward bias as traders price in the higher target, though the Hold rating limits momentum versus a buy upgrade.

Evidence & confidence

The article provides only an analyst PT change and reiteration of Hold, with no new company-specific operational or financial datapoint.

Market effects

Minimal, as this is a single-name analyst target change without broader sector guidance or regulatory/product developments.

None indicated.

None indicated.

Counterpoint

A higher price target with a maintained Hold can signal the upside is largely already reflected, reducing the odds of sustained buying pressure.

Key entities

  • Tempus AI

    Subject of the analyst note, rated Hold with an increased price target to $89 from $73.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.